Biological
ChAdOx1 nCoV-19 clinical trials
Also written AZD1222, Covishield and Vaxzevria.
- studies test it
- 27
- open now
- 0
- in phase 3
- 9
- first study started
- 2020
How studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2021 (16)
| Year | Studies |
|---|---|
| 2020 | 6 |
| 2021 | 16 |
| 2022 | 4 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 12
- Phase 3
- 9
- Phase 4
- 6
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 20
Who runs them
Industry 11 · Other 16
AstraZeneca (5) · University of Oxford (4) · R-Pharm (3) · Medigen Vaccine Biologics Corp. (2) · Federal University of Espirito Santo (2) · Jens D Lundgren, MD (1) · Albert B. Sabin Vaccine Institute (1) · Universiteit Antwerpen (1)
Often tested with
Tested in the same studies.
BNT162 Vaccine (5) · R-AD26-S (recombinant adenovirus type 26 carrying THE gene FOR severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike glycoprotein) (3) · 2019-nCoV Vaccine mRNA-1273 (2) · MenACWY (1) · Acetaminophen (1) · ChAdOx1-vectored COVID-19 Variant Vaccine AZD2816 (1) · Sinovac COVID-19 vaccine (1) · BBV152 COVID-19 vaccine (1)
Studies
Open first, then newest update. How each study uses ChAdOx1 nCoV-19 is read from its arms, and is right about nine times in ten.
Testing it · 27
- Investigating a Vaccine Against COVID-19CompletedPhase 2/3University of OxfordNCT04400838Written as ChAdOx1 nCoV-19 (Abs 260)
- A Study of a Candidate COVID-19 Vaccine (COV001)CompletedPhase 1/2University of OxfordNCT04324606Written as ChAdOx1 nCoV-19
- A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised AdultsTerminatedPhase 4AstraZenecaNCT05057897Written as AZD1222
- Phase II/III Study of AZD2816, for the Prevention of COVID-19 in AdultsCompletedPhase 2/3AstraZenecaNCT04973449Written as AZD1222
- National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)CompletedPhase 4Jens D Lundgren, MDNCT04760132Written as COVID-19 Vaccine AstraZeneca suspension for injection
- Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)WithdrawnPhase 3Murdoch Childrens Research InstituteNCT05387317Written as AstraZeneca Standard dose
- Study of AZD1222 for the Prevention of COVID-19 in JapanCompletedPhase 1/2AstraZenecaNCT04568031Written as AZD1222
- Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in AdultsCompletedPhase 3AstraZenecaNCT04516746Written as AZD1222
- Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing TrialCompletedPhase 4Albert B. Sabin Vaccine InstituteNCT05343871Written as AZD1222
- Immunogenicity After COVID-19 Vaccines in Adapted SchedulesCompletedPhase 4Universiteit AntwerpenNCT06189040Written as ChAdOx1-S [Recombinant]
- Antibody Response to COVID-19 Vaccines in Liver Disease PatientsCompletedPhase 4Humanity & Health Medical Group LimitedNCT04775069Written as AZD1222
- Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and DeathCompletedPhase 4Shabir MadhiNCT04914832Written as AZD1222
- A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19CompletedPhase 2Medigen Vaccine Biologics Corp.NCT05197153Written as AZD1222
- Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2CompletedPhase 3Botswana Harvard AIDS Institute PartnershipNCT05715944Written as AZD 1222
- Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)CompletedPhase 1/2R-PharmNCT04760730Written as AZD1222
- A Study of Intranasal ChAdOx1 nCOV-19CompletedPhase 1University of OxfordNCT04816019Written as ChAdOx1 nCov-19
- Efficacy and Safety of Heterologous and Homologous COVID-19 VaccinationCompletedNot applicableNational Taiwan University HospitalNCT05074368Written as ChAdOx1-nCov-19 (Astra-Zeneca)
- Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster DoseCompletedPhase 3Bharat Biotech International LimitedNCT05567471Written as Covishield
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in AdultsCompletedPhase 3Medigen Vaccine Biologics Corp.NCT05011526Written as AZD1222
- Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 PreventionCompletedPhase 2R-PharmNCT04686773Written as AZD1222
See all 27 studies that test ChAdOx1 nCoV-19 →
As the comparator · 9 — what is tested is compared with ChAdOx1 nCoV-19
- The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)CompletedPhase 2/3Vinbiocare Biotechnology Joint Stock CompanyNCT05012943Written as Astra Zeneca COVID-19 vaccine
- Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.CompletedPhase 2/3Laboratorio Avi-Mex, S.A. de C.V.NCT05710783Written as ChAdOx-1-S[recombinant]
- Mix and Match of the COVID-19 Vaccine for Safety and ImmunogenicityActive, not recruitingPhase 2Canadian Immunization Research NetworkNCT04894435Written as ChAdOx1-S [recombinant]
- A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and OlderCompletedPhase 3EuBiologics Co.,LtdNCT05603052Written as ChAdOx1 nCoV-19
- A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy AdultsCompletedPhase 3EuBiologics Co.,LtdNCT05572879Written as ChAdOx1 nCoV-19
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and AboveCompletedPhase 3Medigen Vaccine Biologics Corp.NCT05198596Written as AZD1222
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222CompletedPhase 3Medigen Vaccine Biologics Corp.NCT05426343Written as AZD1222
- COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222CompletedPhase 3Valneva Austria GmbHNCT04864561Written as AZD1222
- Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and OlderStatus unknownPhase 3Everest Medicines (Singapore) Pte. Ltd.NCT05534035Written as Vaxzevria®
Codes
What other systems call ChAdOx1 nCoV-19 · ClinicalTrials.gg INT006860
- MeSH (NLM) D000090985ChAdOx1 nCoV-19One source NLM
- UNII (FDA) B5S3K2V0G8AZD-1222Confirmed FDA, NLM
- NCI Thesaurus C173021ChAdOx1 nCoV-19 VaccineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000090985 | ChAdOx1 nCoV-19 | One source NLM |
| UNII (FDA) | B5S3K2V0G8 | AZD-1222 | Confirmed FDA, NLM |
| NCI Thesaurus | C173021 | ChAdOx1 nCoV-19 Vaccine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.